DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Samir Seleq, PGY2 House Officer, Auckland Public Hospital, New Zealand; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, June 2015.
Sézary syndrome is an erythrodermic form of cutaneous T-Cell lymphoma (CTCL), a term that collectively includes all cutaneous lymphomas arising from T lymphocytes. The syndrome is named after Albert Sézary, a French dermatologist born in 1880. It is also called Sezary syndrome.
T lymphocytes are circulating immune cells that mature in the thymus. In Sézary syndrome, malignant T lymphocytes in the peripheral blood clonally match malignant T cells found in the skin.
Sézary syndrome is a disease of older adults. Epidemiological data is not available in New Zealand. Worldwide, incidence appears to be 0.8–0.9 per million with a male to female ratio of 2:1. It is not an inherited disease.
The cause of Sézary syndrome remains largely unclear. The malignant T cells in the skin and blood have the following characteristics:
This contributes to endogenous immunosuppression.
Patients with Sézary syndrome present with diffusely red, thickened and scaly skin. Pruritus (itch) is common, often severe, and can be difficult to manage. Other features may include:
These symptoms often lead to lack of sleep, anxiety and depression.
Very rarely, Sézary syndrome has been reported to present with pruritus, Sézary cells on biopsy of normal-looking skin, and no visible rash.
Other features of Sézary syndrome include:
The following malignancies are associated with Sézary syndrome:
Sézary syndrome should be considered in any erythrodermic patient. Diagnosis requires clinicopathological correlation.
If possible, select an area of indurated skin for biopsy. Multiple biopsies are useful especially if morphology varies.
Features on light microscopy may include:
Sézary cells are large atypical mononuclear cells with a large cerebriform nuclei. They are found in large numbers in the peripheral blood of patients with Sézary syndrome. Smaller numbers may be found in healthy patients or those with other diseases.
Flow cytometry can demonstrate CD4+CD7- and CD4+CD26- T cells, which are characteristic of Sézary syndrome. T-cell antigens may also be absent (CD2, CD3, CD4 and/or CD5). The CD4:CD8 ratio is > 10, but is not diagnostic.
Excisional biopsies are required to distinguish between dermatopathic lymph node changes and reactive lymph node changes.
T-cell receptor (TCR) gene rearrangement tests may be performed on the skin specimen, circulating blood and lymph nodes. This test evaluates clonality of the cells, which should be similar in the 3 sites.
Other diagnoses considered in an erythrodermic patient may include:
Treatment for Sézary syndrome is determined by the stage of disease and comorbidities.
TNMB criteria for staging CTCL are skin (T), lymph node (N), visceral involvement (M), blood (B). Sézary syndrome is classified as at least T4B2 (T4 erythroderma and B2 peripheral blood involvement). Classification also depends on lymph node or internal organ involvement:
There is no standard therapy for Sézary syndrome. Patients are prescribed topical and systemic medications. They may also receive UVB or PUVA phototherapy, and/or radiotherapy (localised superficial rays or total skin electron beam therapy).
Examples of topical therapy used to treat Sézary syndrome include:
ECP is an immune-sparing therapy in which a photosensitizing agent (psoralen/8-methoxsalen) is combined with UVA to treat peripheral bloodwhich is extracted, irradiated and returned to the patient. It is the preferred first line therapy in early stages.
Biologics are preferably used in conjunction with photopheresis. However, they can be used as part of single or multi-agent regimes if ECP is not available. They include:
Medications are often used in combination.
Examples of chemotherapy agents used for Sézary syndrome are:
Sézary syndrome is usually aggressive and prognosis is generally poor with a median survival between 2–4 years. Patients may respond transiently but relapse is often inevitable. The occasional patient has gone into remission after treatment.
Patients usually succumb to opportunistic infections due to immune suppression.
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.